Regents of the University of Minnesota;The University Of North Carolina At Chapel Hill;Albert-Ludwigs-Universitaet Freiburg;St. Jude Children's Research Hospital
发明人:
BLAZAR, Bruce R.,KOEHN, Brent H.,MURRAY, Peter J.,TING, Jenny P. Y.,ZEISER, Robert,MILLER, Jeff S.
申请号：
HK18116031
公开号：
HK1256917A1
申请日:
2018.12.13
申请国别(地区):
HK
年份:
2019
代理人:
摘要：
In one aspect, a method of treating a subject having or at risk of having graft-versus-host disease (GvHD) generally includes administering to the subject a plurality of myeloid-derived suppressor cells (MDSCs) effective to ameliorate at least one symptom or clinical sign of graft-versus-host disease compared to a suitable control subject. In another aspect, a method of treating a tumor in a subject generally includes administering to the subject an anti-tumor therapy and co-administering to the subject an inflammasome inciting agent in an amount effective to increase inflammasome activation of MDSCs sufficiently to reduce suppressor function of the MDSCs.
